Comparison of Direct and Indirect Measurement of LDL-C in HIV-Infected Individuals: ACTG 5087

REFERENCES

• The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993–2003.
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479–2486.
   Google Scholar
• Field Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised con-trolled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Enql J Med. 2005;352:48–62.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immuno-deficiency syndrome. Am J Med. 1989;86:27–31.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan SS. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-nafve cohort. HIV Med. 2005;6: 114–121.
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H. Triglycerides and atherosclero-sis; results from the Prospective Cardiovascular Munster Study. Arterioscler Rev. 199122: 51–57.
   Google Scholar
• Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Pro-gram (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treat-ment Panel III). JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Cullen P. Evidence that triglycerides are an indepen-dent coronary heart disease risk factor. Am J CardioL 2000;86:943–949.
   PubMed Web of Science ®Google Scholar
• Assmann G. Pro and con: high-density lipoprotein, triglyc-erides, and other lipid subfractions are the future of lipid management. Am J CardioL 2001;87:2B–7B.
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ;18(6):449–502.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Zackin RA, Brobst SW, et al., for the ACTG 5087 team. A prospective, multicenter randomized trial compar-ing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: ACTG 5087. AIDS Res Hum Retro viruses. 2005;21: 757–767.
   Google Scholar
• Lin L, Hedayat AS, Sinha BK, Yang M. Statistical methods in assessing agreement: models, issues, and tools. J Am Stat Assoc. 2002 ;97(457):257–270.
   Web of Science ®Google Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–310.
   PubMed Web of Science ®Google Scholar
• Miller WG, Waymack PP, Anderson FP, Ethridge SF, Jayne EC. Performance of four homogeneous direct methods for LDL-C-cholesterol. Clin Chem. 2002;48:489–498.
   Google Scholar
• Nauck M, Rifai N. Analytical performance and clinical effi-cacy of three routine procedures for LDL-C cholesterol mea-surement compared with the ultracentrifugation-dextran su !fate- M g (2 +) method. Clin Chim Acta. 2000;294:77–92.
   PubMed Web of Science ®Google Scholar
• Pisani T, Gebski CP, Leary ET, Warnick GR, Wington JF. Ac-curate direct determination of low-density lipoprotein cho-lesterol using an immunoseparation reagent and enzymatic cholesterol assay. Arch Pathol Lab Med. 1995;119: 1127–1135.
   PubMed Web of Science ®Google Scholar
• Cobbaert C, Broodman I, Swart GR, Hoogerbrugge N. Performance of a direct, immunoseparation based LDL-C-cholesterol method compared to Friedewald calculation and a polyvinyl sulphate precipitation method. Eur J Clin Chem Clin Biochem. 1995;33:417–424.
   PubMedGoogle Scholar
• Gerber JG, Kitch DW, Aberg JA, et al. The safety and ef-ficacy of fish oil in combination with fenofibrate (FF) in sub-jects on ART with hypertriglyceridemia (HTG) who had an incomplete response to either agent alone: results of ACTG A5186. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, CO. Oral presentation 146.
   Google Scholar
• Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation of and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving an-tiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37: 613–627.
   PubMed Web of Science ®Google Scholar
• Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease in-hibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem. 2001;276:37514–37519.
   PubMed Web of Science ®Google Scholar
• Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res. 2003;42:81–92.
   PubMed Web of Science ®Google Scholar
• Carr A. HIV lipodystrophy: risk factors, pathogenesis, di-agnosis and management. AIDS. 2003;17\(suppl 1):S141–148.
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG. Interactions between antiret-roviral drugs and drugs used for the therapy of the meta-bolic complications encountered during HIV infection. Clin PharmacokineL 2002;41:1195–1211.
   Google Scholar
• Tungsiripat M, Aberg JA. Dyslipidemia in HIV-infected individuals. Invited review. Cleveland Clinic J Med. 2005;72:1113–1120.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Rosenkranz S, Fichtenbaum CJ, Alston B, Brobst SW, Segal Y, Gerber JG. Pharmacokinetic interac-tion between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS. 2006;20: 725–729.
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rosenkranz S, Fichtenbaum CJ, et al. The ef-fect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of ACTG 5108 Study. JAIDS. 2005;39:307–312.
   Google Scholar
• Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-tors atorvastatin and simvastatin. Antimicrob Agents Che-mother 2001;45:3445–3450.
   PubMed Web of Science ®Google Scholar
• Carr R, Andre A, Bertz R. Concomitant administration of ABT-378/ritonavir (ABT-378/r). Results in a clinically im-portant pharmacokinetic (PK) interaction with atorvastatin but not pravastatin. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Che-motherapy, September 17–20,2000. Abstract 1644.
   Google Scholar